2024 ICD-10-CM Diagnosis Code E88.1

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

• Acquired generalized lipodystrophy
• Acquired partial lipodystrophy
• Acquired partial lipodystrophy
• Acquired partial lipodystrophy
• Adverse reaction following injection of substance
• Adverse reaction following injection of substance
• Adverse reaction following injection of substance
• AKT2-related familial partial lipodystrophy
• Autosomal semi-dominant severe lipodystrophic laminopathy
• CIDEC-related familial partial lipodystrophy
• Congenital abnormal shape of clavicle
• Congenital abnormal shape of clavicle
• Congenital anomaly of subcutaneous tissue
• Congenital anomaly of subcutaneous tissue
• Congenital anomaly of subcutaneous tissue
• Congenital anomaly of subcutaneous tissue
• Congenital deformity of clavicle
• Congenital deformity of clavicle
• Congenital deformity of shoulder
• Congenital deformity of shoulder
• Congenital generalized lipodystrophy
• Congenital generalized lipodystrophy
• Congenital generalized lipodystrophy
• Diabetes mellitus due to genetic defect in insulin action
• Familial partial lipodystrophy
• Familial partial lipodystrophy Dunnigan type
• Familial partial lipodystrophy Kobberling type
• Generalized congenital lipodystrophy with myopathy
• Genetic lipodystrophy
• Glucose-galactose malabsorption
• Glucose-galactose malabsorption
• Insulin adverse reaction
• Insulin lipoatrophy
• Insulin resistance
• Insulin resistance
• Keppen Lubinsky syndrome
• LIPE-related familial partial lipodystrophy
• Lipoatrophic diabetes
• Lipoatrophy
• Lipoatrophy and lipodystrophy
• Lipoatrophy caused by antiretroviral drug
• Lipoatrophy due to injected corticosteroid
• Lipoatrophy due to injected drug
• Lipoatrophy due to injected drug
• Lipoatrophy due to injected drug
• Lipodystrophia centrifugalis abdominalis infantalis
• Lipodystrophy
• Lipodystrophy caused by antiretroviral drug
• Lipodystrophy due to juvenile dermatomyositis
• Lipodystrophy due to peptidic growth factors deficiency
• Lipodystrophy of face
• Lipodystrophy, intellectual disability, deafness syndrome
• Lipodystrophy, partial, with Rieger anomaly, short stature, and insulinopenic diabetes mellitus
• Localized idiopathic lipoatrophy
• Localized lipoatrophy
• Localized lipoatrophy
• Localized lipoatrophy
• Localized lipoatrophy
• Localized lipodystrophy
• Loss of subcutaneous fat
• Loss of subcutaneous fat overlying triceps muscle
• Malabsorption of glucose
• Malabsorption of glucose
• Mandibuloacral dysostosis
• Mandibuloacral dysostosis
• Mandibuloacral dysplasia with type A lipodystrophy
• Mandibuloacral dysplasia with type B lipodystrophy
• Marfan's syndrome
• Membranous lipodystrophy
• Nakajo-Nishimura syndrome
• Panniculitis induced localized lipodystrophy
• Partial face-sparing lipodystrophy
• Perilipin 1 related familial partial lipodystrophy
• Post-inflammatory lipoatrophy
• PPARG-related familial partial lipodystrophy
• Progeroid and marfanoid aspect, lipodystrophy syndrome
• Semicircular lipoatrophy
• Severe neurodegenerative syndrome with lipodystrophy
• Widespread lipoatrophy

Clinical Information

• HIV-Associated Lipodystrophy Syndrome

  defective metabolism leading to fat maldistribution in patients infected with hiv. the etiology appears to be multifactorial and probably involves some combination of infection-induced alterations in metabolism, direct effects of antiretroviral therapy, and patient-related factors.

• Lipodystrophy

  a collection of heterogenous conditions resulting from defective lipid metabolism and characterized by adipose tissue atrophy. often there is redistribution of body fat resulting in peripheral fat wasting and central adiposity. they include generalized, localized, congenital, and acquired lipodystrophy.

• Lipodystrophy, Congenital Generalized

  congenital disorders, usually autosomal recessive, characterized by severe generalized lack of adipose tissue, extreme insulin resistance, and hypertriglyceridemia.

• Lipodystrophy, Familial Partial

  inherited conditions characterized by the partial loss of adipose tissue, either confined to the extremities with normal or increased fat deposits on the face, neck and trunk (type 1), or confined to the loss of subcutaneous fat from the limbs and trunk (type 2). type 3 is associated with mutation in the gene encoding peroxisome proliferator-activated receptor gamma.

• Lipomatosis, Multiple Symmetrical

  a condition characterized by the growth of unencapsulated masses of adipose tissue symmetrically deposited around the neck, shoulders, or other sites around the body.

• Panniculitis, Peritoneal

  inflammation of the underlying layer of adipose tissue (panniculus) of the peritoneum, usually of the mesentery or the omentum. there are several forms with various names and are usually characterized by infiltration of lymphocytes and neutrophils, fat necrosis, and fibrosis.

• Whipple Disease

  a chronic systemic infection by a gram-positive bacterium, tropheryma whippelii, mainly affecting the small intestine but also the joints; cardiovascular system; and the central nervous system. the disease is characterized by fat deposits in the intestinal mucosa and lymph nodes, malabsorption, diarrhea with fatty stools, malnutrition, and arthritis.

• Insulin Resistance

  diminished effectiveness of insulin in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent hyperglycemia or ketosis.

• Metabolic Syndrome

  a cluster of symptoms that are risk factors for cardiovascular diseases and type 2 diabetes mellitus. the major components of metabolic syndrome include abdominal obesity; atherogenic dyslipidemia; hypertension; hyperglycemia; insulin resistance; a proinflammatory state; and a prothrombotic (thrombosis) state.

• HIV

  human immunodeficiency virus. a non-taxonomic and historical term referring to any of two species, specifically hiv-1 and/or hiv-2. prior to 1986, this was called human t-lymphotropic virus type iii/lymphadenopathy-associated virus (htlv-iii/lav). from 1986-1990, it was an official species called hiv. since 1991, hiv was no longer considered an official species name; the two species were designated hiv-1 and hiv-2.

• Adipose Tissue

  specialized connective tissue composed of fat cells (adipocytes). it is the site of stored fats, usually in the form of triglycerides. in mammals, there are two types of adipose tissue, the white fat and the brown fat. their relative distributions vary in different species with most adipose tissue being white.

• Acquired Partial Lipodystrophy

  partial lipodystrophy, the cause of which is not present at birth. examples include lipodystrophy associated with human immunodeficiency virus (hiv) therapy, and barraquer-simons syndrome, associated with c3 nephritic factor.

• Homeostatic Model Assessment of Insulin Resistance

  an assessment of beta-cell function and insulin resistance based on fasting blood glucose and insulin concentrations.

• Hyperandrogenism, Insulin Resistance, Acanthosis Nigricans Syndrome|HAIR-AN Syndrome

  a condition characterized by hyperandrogenism, insulin resistance, and acanthosis nigricans, typically associated with obesity in teenage girls. it is considered to be a subtype of polycystic ovarian syndrome, but may occur in male individuals. etiology is unclear, but some cases may be associated with mutations affecting the tyrosine kinase domain of the insulin receptor.

• Insulin Receptor Mutation - Associated Insulin Resistance Syndromes

  insulin resistance caused by inactivating mutation(s) in the insr gene encoding the insulin receptor.

• Insulin Resistance

  decreased sensitivity to circulating insulin which may result in acanthosis nigicrans, elevated insulin level or hyperglycemia.

• Insulin Resistance Measurement|INSULINR|Insulin Resistance|Insulin Resistance

  the determination of the insulin resistance (cells inability to respond to insulin) in a biological specimen.

• Insulin Resistance Syndrome

  a cluster of closely related metabolic abnormalities associated with insulin resistance that confer an increased risk of the development of type 2 diabetes and cardiovascular disease. these abnormalities may include obesity, high blood pressure, abnormal cholesterol levels, proteinuria, and/or polycystic ovary syndrome.

• Insulin Resistant Diabetes Mellitus with Acanthosis Nigricans and Hyperandrogenism|Type A Insulin Resistance Syndrome

  a syndrome of insulin resistance caused by mutation(s) in the insr gene, encoding the insulin receptor. this condition is characterized by a clinical triad of hyperinsulinemia, acanthosis nigricans, and hyperandrogenism without lipodystrophy. this is the least severe of a spectrum of disorders; the other two conditions are rabson-mendenhall syndrome and donohoe syndrome.

• Obesity-Associated Insulin Resistance

  insulin resistance associated with obesity, which may be attributed in part to impaired insulin signaling in target tissues, or impaired insulin-stimulated glucose transport due to reduced expression of the glucose transporter protein 4.

• Acquired Generalized Lipodystrophy

  generalized lipodystrophy, the cause of which is not present at birth.

Convert E88.1 to ICD-9-CM

• ICD-9-CM Code: 272.6 - Lipodystrophy

Patient Education

Metabolic Disorders

Metabolism is the process your body uses to get or make energy from the food you eat. Food is made up of proteins, carbohydrates, and fats. Chemicals in your digestive system break the food parts down into sugars and acids, your body's fuel. Your body can use this fuel right away, or it can store the energy in your body tissues, such as your liver, muscles, and body fat.

A metabolic disorder occurs when abnormal chemical reactions in your body disrupt this process. When this happens, you might have too much of some substances or too little of other ones that you need to stay healthy. There are different groups of disorders. Some affect the breakdown of amino acids, carbohydrates, or lipids. Another group, mitochondrial diseases, affects the parts of the cells that produce the energy.

You can develop a metabolic disorder when some organs, such as your liver or pancreas, become diseased or do not function normally. Diabetes is an example.

Code History

• FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
• FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
• FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
• FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
• FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
• FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
• FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
• FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
• FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.